Flagship Biosciences Presents PD-L1 Scoring Method at SITC 2017 that could Eliminate Reliance on Complex Multiplex IHC Assays

Novel cTA™-based morphometric biomarker interpretation approach quantifies immune cells in tumor tissues and has potential to revolutionize PD-L1 diagnostics landscape

National Harbor, MD – November 11th 2017 – Flagship Biosciences, Inc., the leading developer of quantitative tissue biomarker interpretations for clinical development of tissue-based diagnostics to drive clinical decisions for industry partners, presented data today on the development of an immuno-oncology biomarker interpretation approach at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) – happening now through November 12, 2017, at the Gaylord National Harbor Convention Center.

Flagship Scientist Allison Harney presented scientific poster, #P.36, entitled Computational Tissue Analysis–Based Quantification of Tumor-Infiltrating Leukocytes Using Morphometrics in Immunohistochemistry Stained NSCLC Samples.

See the full poster here.

The poster shows how Flagship’s Computational Tissue Analysis (cTA™) platform is able to use morphometric features of immune, tumor, and stromal cells, stained with routine immunohistochemistry (IHC), to interpret PD-L1 and leukocyte within the tumor microenvironment. This methodology could lead to an approach for patient selection that is founded on existing PD-L1 companion diagnostics and eliminates reliance on time consuming and risky new IHC assays needing regulatory review and approval. This method captures important biological information needed to understand immune infiltrates within tissue context.

“SITC is a place where innovators share ideas for understanding the role of the immune system in cancer, and the poster we presented this year demonstrates how our cTA™ technology can be used to drive forward immuno-oncology research and drug development. We are very excited to share our novel approaches with the SITC community.” said Flagship Chief Scientific Officer, Dr. Joseph Krueger.

For more information on Flagship’s presence at SITC, visit the company’s website here.

About SITC

The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Established in 1984, SITC, a 501(c)(3) not-for-profit organization, serves scientists, clinicians, academicians, patients, patient advocates, government representatives and industry leaders from around the world. Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word “cure” a reality for cancer patients everywhere.

About Flagship Biosciences

Flagship Biosciences helps drug developers confidently define their path to success. Our Computational Tissue Analysis (cTA™) platform provides the quantitative, contextual tissue interpretation necessary to make timely decisions.

With a unique combination of our technology platform, extensive expertise across multiple disciplines (e.g., pathology, biology, image analysis, software engineering), and an in-house CLIA lab, Flagship Biosciences develops quantitative tissue biomarker interpretations for clinical development of tissue-based diagnostics, including companion diagnostics (CDx). We collaborate with biopharmaceutical teams at every stage of the clinical trial to:

  • Make informed pipeline decisions that will accelerate the right clinical path
  • Enable critical go/no go decisions based on confirmation of action
  • Design, implement and evaluate prototype diagnostic strategies
  • Differentiate commercial strategies to increase probability of success

Over 100 pharmaceutical, biotech, and medical device firms rely on Flagship’s technology for success. As the largest clinical tissue-image-analysis operation in the US, Flagship has completed over 400 projects since 2009.

Media Contact
Aaron Young
Marketing Associate, Flagship Biosciences, Inc.

Share This Post: